指南与共识白血病

急性早幼粒细胞白血病的治疗:欧洲白血病专家组的更新建议

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
指南 / 共识 · Blood · 2019-02-25

欧洲白血病专家组基于2009年后研究进展更新急性早幼粒细胞白血病管理建议。内容涵盖遗传学诊断、风险 adapted 前线治疗、挽救治疗、并发症管理、分子学反应评估及特殊人群处理。早期死亡和高危患者治疗优化仍是主要挑战。

要点

  • 更新前线治疗建议,强调三氧化二砷(ATO)在 frontline 治疗中的作用
  • 涵盖遗传学诊断、风险 adapted 治疗、挽救治疗及分子学反应评估
  • 针对出血性疾病 APL 分化综合征、QT 间期延长等并发症给出具体建议

核心结论

  • 欧洲白血病专家组基于证据和专家意见更新了 APL 管理建议,涵盖前线治疗和复发 settings。
  • 早期死亡(仍发生在诱导治疗前和诱导治疗期间)和高危患者治疗优化是 APL 剩余的主要挑战。

研究设计与样本

  • 欧洲白血病专家组对 2009 年建议后有关 APL 管理(尤其是 ATO 在前线治疗中的作用)的研究进展进行综述并制定更新建议。

主要发现

  • 自 2009 年综合建议以来,多项研究提供了重要见解,特别是关于三氧化二砷(ATO)在前线治疗中的作用。
  • 更新建议涉及遗传学诊断、现代风险 adapted 前线治疗、挽救治疗、关键并发症(APL 分化综合征、QT 间期延长、全反式维甲酸和 ATO 相关毒性)的识别与管理,以及分子学反应评估。
  • 特殊情况的处理包括儿童、老年和妊娠患者的 APL 管理。

关键数值与推荐

  • 原文未报告具体推荐等级或数值标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion-based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-trans retinoic acid- and ATO-related toxicities, as well as recommendations for molecular assessment of the response to treatment. Finally, the approach to special situations is also discussed, including management of APL in children, elderly patients, and pregnant women. The most important challenges remaining in APL include early death, which still occurs before and during induction therapy, and optimizing treatment in patients with high-risk disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019. PMID: 30803991. doi:10.1182/blood-2019-01-894980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。